Atrial fibrillation (AF) is the most common arrhythmia worldwide and it is associated with a 3–5-fold higher risk of stroke [1]. This risk has been significantly reduced after the introduction of oral anticoagulants (OAC), that should be prescribed in all patients who are not considered at very low-risk of thromboembolism (i.e.: CHA2DS2-VASc Score 0 in males and 1 in females) as recommended by current guidelines on AF [2–5].